Malignant Urinary Tract Neoplasm — Research

Malignant Urinary Tract Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-12	559	`("Malignant Urinary Tract Neoplasm"[tiab] OR "Urinary Tract Cancer"[tiab] OR "Malignant Urinary Tract Tumor"[tiab])`	2026-09-12	pubmed
Last 5 years	2021-01-01 → 2026-12-31	185	`("Malignant Urinary Tract Neoplasm"[tiab] OR "Urinary Tract Cancer"[tiab] OR "Malignant Urinary Tract Tumor"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-12	pubmed
Last 12 months	2025-09-12 → 2026-09-12	27	`("Malignant Urinary Tract Neoplasm"[tiab] OR "Urinary Tract Cancer"[tiab] OR "Malignant Urinary Tract Tumor"[tiab]) AND (2025/09/12:2026/09/12[dp])`	2026-09-12	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (152)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 126–150 of 152 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
· Cancer Discov · 2014 · PMID 24625776 · validated civic_curation pubmed
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
· Eur Urol · 2016 · PMID 25636205 · validated civic_curation pubmed
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.